Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 26;8(3):00138-2022.
doi: 10.1183/23120541.00138-2022. eCollection 2022 Jul.

Eosinophilic cationic protein as marker for response to antibody therapy in severe asthma

Elisa Franceschi  1 , Nora Drick  2 , Jan Fuge  2   3 , Tobias Welte  2   3 , Hendrik Suhling  2
Affiliations

Eosinophilic cationic protein as marker for response to antibody therapy in severe asthma

Elisa Franceschi et al. ERJ Open Res. .

Abstract

This study of the eosinophil cationic protein (ECP) as predictor of clinical response to biological therapy in severe asthma found that ECP is not useful in unselected patients but may have a role in those not exposed to oral corticosteroids. https://bit.ly/398RwEk.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors declare that they have no competing interests

References

    1. Fan Chung K, Wenzel SE, Brozek JL, et al. . International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373. doi:10.1183/13993003.52020-2013 - DOI - PubMed
    1. Pavord ID, Korn S, Howarth P, et al. . Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651–659. doi:10.1016/S0140-6736(12)60988-X - DOI - PubMed
    1. Nair P, Wenzel S, Rabe KF, et al. . Oral glucocorticoid–sparing effect of benralizumab in severe asthma. N Engl J Med 2017; 376: 2448–2458. doi:10.1056/NEJMoa1703501 - DOI - PubMed
    1. Drick N, Seeliger B, Welte T, et al. . Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response. BMC Pulm Med 2018; 18: 119. doi:10.1186/s12890-018-0689-2 - DOI - PMC - PubMed
    1. Kobayashi K, Nagase H, Sugimoto N, et al. . Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma. Asia Pac Allergy 2021; 11: e31. doi:10.5415/apallergy.2021.11.e31 - DOI - PMC - PubMed